- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02099578
The Effects of Strawberries on Blood Pressure in Postmenopausal Women
Daily Incorporation of Strawberries Into a Diet Favorably Improves Vascular Function and Lowers Aortic Blood Pressure in Postmenopausal Women With Prehypertension
Cardiovascular disease (CVD) is the leading cause of death in the US. Statistics show that approximately 91% of individuals with CVD have vascular dysfunction. Hypertension is a major modifiable risk factor for CVD and approximately 60% of adults in the US are pre-hypertensive and hypertensive. In addition, the prevalence of hypertension is associated with aging in both genders; however, the increase in blood pressure (BP) in women after menopause exceeds that of men.
The development of effective and safe strategies to improve vascular function is of significance as it can have a great impact on quality of life, productivity and economic burden for the affected populations. One such alternative would be to introduce into the diet food sources that are rich in naturally occurring bioactive compounds. Thus, the long-term goal of the investigators is to provide feasible and effective dietary ways for postmenopausal women to improve their vascular function and quality of life.
Strawberries are a rich source of bioactive compounds and its total antioxidant content ranks third among all fruits and vegetables. Hence, the purpose of this study is to bring forth evidence that incorporation of strawberries into the diet will reduce blood pressure and improve cardiovascular function in pre- and stage 1-hypertensive postmenopausal women.
Sixty eligible postmenopausal women between the ages of 45 and 65 and a seated BP of ≥ 130/85 mm Hg but ≤ 160/100 mmHg at the screening visit will be randomly assigned to one of three groups:
- 25 g freeze-dried strawberry powder;
- 50 g freeze-dried strawberry powder; or
- placebo powder. Participants will be asked to consume the supplements for 8-weeks. Medical history, medication use, dietary intake, and physical activity will be assessed at 0-, 4-, and 8-weeks followed by blood draw. Serum levels of markers of cardiovascular function as well as oxidative stress and inflammation will be measured.
The investigators hypothesize that regular consumption of strawberry will improve cardiovascular function, decrease BP and blood markers of oxidative stress as well as inflammation. Investigators also expect the findings of this study to provide a foundation for further studies to examine the effects of long-term incorporation of strawberry into the diet and the integrity of cardiovascular system.
Study Overview
Status
Conditions
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Florida
-
Tallahassee, Florida, United States, 32306
- Florida State University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Postmenopausal women (1 to 10 years after natural menopause or bilateral oophorectomy)
- 45-65 years of age
- Seated blood pressure ≥ 130/85 mm Hg but ≤ 160/100 mm Hg
- BMI > 25 but < 40 kg/m2
Exclusion Criteria:
- Seated blood pressure ≤ 129/84 or ≥160/101 mmHg
- Type I Diabetes
- Cardiovascular disease
- Active cancer
- Glaucoma
- Thyroid disease
- Kidney disease
- Liver disease
- Pancreatic disease
- Enrollment in a weight loss program
- Heavy smokers (>20 cigarettes per day)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: FACTORIAL
- Masking: DOUBLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
PLACEBO_COMPARATOR: Control Group
Freeze-dried placebo powder - two doses of 25 g/day for 8 weeks
|
Participants will be given two packets of 25 g of placebo powder and asked to consume one packet in the morning and one at night.
Other Names:
|
|
ACTIVE_COMPARATOR: 25 g of Freeze-dried Strawberry Powder
Freeze-dried strawberry and placebo powder - one dose of 25 g/day of each for 8 weeks
|
Participants will be given two packets of 25 g of placebo powder and asked to consume one packet in the morning and one at night.
Other Names:
Participants will be given one packet of 25 g of freeze-dried strawberry powder and one packet of 25 g of placebo powder and asked to consume one packet in the morning and one at night.
Other Names:
|
|
EXPERIMENTAL: 50 g of Freeze-dried Strawberry Powder
Freeze-dried strawberry powder - two doses of 25 g/day for 8 weeks
|
Participants will be given two packets of 25 g of freeze-dried strawberry powder and asked to consume one packet in the morning and one at night.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Blood Pressure
Time Frame: 8 weeks
|
By measuring blood pressure variability and baroreflex sensitivity at rest and during physiological stress (handgrip exercise and post-exercise muscle ischemia).
|
8 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Arterial Stiffness
Time Frame: 8 weeks
|
By assessing pulse wave velocity and augmentation index at rest and during physiological stress (handgrip exercise and post-exercise muscle ischemia).
|
8 weeks
|
|
Endothelial function
Time Frame: 8 weeks
|
By assessing blood biomarkers of vascular function (adiponectin, leptin, endothelin-1, angiotensin II and 8-isoprostane).
|
8 weeks
|
|
Oxidative Stress
Time Frame: 8 weeks
|
By assessing blood biomarkers of oxidative stress (superoxide dismutase, nitrate/nitrite, 8-isoprostane, malondialdehyde , and oxidized low density lipoprotein).
|
8 weeks
|
|
Inflammation
Time Frame: 8 weeks
|
By assessing blood biomarkers of inflammation (tumor necrosis factor-α and C-reactive protein).
|
8 weeks
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Arturo Figueroa, PhD, Florida State University
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2013.11762
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cardiovascular Diseases
-
Weill Medical College of Cornell UniversityAmerican Heart AssociationRecruitingCardiovascular | Cardiovascular Health | Cardiovascular (CV) Risk | Cardiovascular Disease (CVD) Risk FactorsUnited States
-
Hull University Teaching Hospitals NHS TrustNot yet recruitingCardiovascular Surgery | Cardiovascular Diseases (CVD)United Kingdom
-
Fu Jen Catholic UniversityRecruitingCardiovascular Disease | Cardiovascular SurgeryTaiwan
-
Medical College of WisconsinNational Center for Complementary and Integrative Health (NCCIH)CompletedCardiovascular Diseases | Cardiovascular Risk Factor | Cardiovascular HealthUnited States
-
Hospital Mutua de TerrassaCompleted
-
Women's College HospitalUniversity Health Network, Toronto; Sunnybrook Health Sciences Centre; Brigham... and other collaboratorsUnknownCARDIOVASCULAR DISEASESCanada, United States
-
IRCCS Policlinico S. DonatoIRCCS San Raffaele; Fondazione Policlinico Universitario Agostino Gemelli IRCCS and other collaboratorsRecruitingCardiovascular Risk | Genetic Cardiovascular RiskItaly
-
Oregon Health and Science UniversityCompletedCardiovascular Disease | Cardiovascular Risk FactorsUnited States
-
Groupe Hospitalier Paris Saint JosephTerminatedCARDIOVASCULAR DISEASESFrance
-
Children's Hospital Medical Center, CincinnatiRecruitingCardiovascular Diseases (CVD)United States
Clinical Trials on Placebo Powder
-
Aimmune Therapeutics, Inc.TerminatedHen Egg AllergyUnited States
-
RiboCor, Inc.Completed
-
University of ManitobaActive, not recruitingHypertension | AlertnessCanada
-
Johns Hopkins UniversityCompletedFood Hypersensitivity | Peanut Hypersensitivity | Immediate HypersensitivityUnited States
-
University of Missouri-ColumbiaCalifornia Table Grape CommissionRecruitingObesity &Amp; OverweightUnited States
-
Prof. Lin ZhixiuCompletedAllergic RhinitisHong Kong
-
Nanjing Reju Therapeutics Co., LtdNot yet recruiting
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.RecruitingA Clinical Study of TQC3721 Inhalation Powder in Patients With Chronic Obstructive Pulmonary DiseaseChronic Obstructive Pulmonary Disease (COPD)China
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Active, not recruitingPulmonary Disease, Chronic ObstructiveChina
-
USDA, Western Human Nutrition Research CenterCompletedInflammation | ObesityUnited States